Filing Analysis
Regulation FD Disclosure
Filed Mar 31, 2026
LOW
Galectin Therapeutics Inc. reported its financial results for the fiscal year ended December 31, 2025, and provided a business update via a press release on March 31, 2026.
Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- Jack W. Callicutt, Chief Financial Officer, signed the report on March 31, 2026.
- The company incorporated by reference a press release (Exhibit 99.1) containing the detailed financial data.
Other SEC Filing
Filed Mar 17, 2026
LOW
Galectin Therapeutics Inc. appointed Dr. Henry Brem, a renowned neurosurgeon and translational medicine expert from Johns Hopkins University, to its Board of Directors effective March 12, 2026. Dr. Brem brings extensive experience in drug delivery systems and clinical research, having previously served as the Neurosurgeon-in-Chief at Johns Hopkins.
Key Facts
- Dr. Henry Brem was appointed to the Board of Directors on March 12, 2026.
- Dr. Brem served as Director of the Department of Neurosurgery at Johns Hopkins from 2000 until 2025.
- He is credited with developing Gliadel® wafers for brain tumors and has published over 416 peer-reviewed papers.
- Dr. Brem will receive standard non-employee director compensation as per the company's existing program.
- There are no reported related-party transactions or arrangements involving Dr. Brem.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.